îæ€çŽ¢
îæ€çŽ¢
î
Unicycive Therapeutics Inc
UNCYîãŠã©ãããªã¹ãã«è¿œå
8.260USD
-0.300-3.50%
çµå€Â 05/15, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
220.54Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± Unicycive Therapeutics Inc äŒæ¥å
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Unicycive Therapeutics Incã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãUNCY
äŒç€ŸåUnicycive Therapeutics Inc
äžå Žæ¥Jun 17, 2021
æé«çµå¶è²¬ä»»è
ãCEOãGupta (Shalabh)
åŸæ¥å¡æ°22
蚌åžçš®é¡Ordinary Share
決ç®ææ«Jun 17
æ¬ç€Ÿæåšå°4300 El Camino Real, Suite 210
éœåžLOS ALTOS
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·94022
é»è©±çªå·16503840642
ãŠã§ããµã€ãhttps://unicycive.com/
äŒæ¥ã³ãŒãUNCY
äžå Žæ¥Jun 17, 2021
æé«çµå¶è²¬ä»»è
ãCEOãGupta (Shalabh)
Unicycive Therapeutics Incã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
åçå èš³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Thu, May 14
æŽæ°æå»: Thu, May 14
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Vivo Capital, LLC
6.70%
Millennium Management LLC
4.39%
Octagon Capital Advisors LP
3.75%
Nantahala Capital Management, LLC
3.52%
Vanguard Capital Management, LLC
3.04%
ä»ã®
78.60%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Vivo Capital, LLC
6.70%
Millennium Management LLC
4.39%
Octagon Capital Advisors LP
3.75%
Nantahala Capital Management, LLC
3.52%
Vanguard Capital Management, LLC
3.04%
ä»ã®
78.60%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Hedge Fund
16.98%
Venture Capital
8.61%
Investment Advisor
4.70%
Individual Investor
2.36%
Investment Advisor/Hedge Fund
1.76%
Research Firm
0.54%
Pension Fund
0.29%
ä»ã®
64.76%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Wed, Apr 1
æŽæ°æå»: Wed, Apr 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2026Q1
75
9.56M
35.81%
+450.87K
2025Q4
65
6.67M
31.03%
-253.32K
2025Q3
61
5.54M
31.38%
-1.91M
2025Q2
62
6.96M
54.51%
-655.75K
2025Q1
65
6.78M
64.49%
-1.12M
2024Q4
62
69.04M
66.51%
+542.97K
2024Q3
57
54.12M
55.45%
+17.71M
2024Q2
48
26.33M
50.66%
-3.75M
2024Q1
46
28.58M
99.15%
+4.37M
2023Q4
45
24.82M
96.62%
+1.55M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Vivo Capital, LLC
1.79M
7.09%
--
--
Dec 31, 2025
Millennium Management LLC
1.17M
4.65%
+157.82K
+15.55%
Jan 16, 2026
Octagon Capital Advisors LP
1.00M
3.96%
--
--
Dec 31, 2025
Nantahala Capital Management, LLC
939.20K
3.72%
--
--
Dec 31, 2025
Great Point Partners, LLC
796.56K
3.16%
--
--
Dec 31, 2025
Gupta (Shalabh K)
597.25K
2.37%
-100.00
-0.02%
Apr 30, 2025
Logos Global Management LP
473.56K
1.88%
--
--
Dec 31, 2025
Citadel Advisors LLC
258.30K
1.02%
+216.63K
+519.81%
Dec 31, 2025
Rosalind Advisors, Inc.
242.49K
0.96%
+242.49K
--
Apr 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
æ¯ç0%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
Jun 17, 2025
Merger
10â1
æ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
Jun 17, 2025
Merger
10â1
